New Haven biopharma Kolltan Pharmaceuticals said it has dosed the first patient with its new cancer drug therapy as it begins Phase 1 clinical testing.
The drug, called KTN3379, was given to a cancer patient at a facility in Michigan. It is a monoclonal antibody that blocks the activity of a particular enzyme thought to play a key role in the growth, survival and resistance of tumors.
Kolltan hopes to show the drug is safe and to record preliminary evidence of antitumor activity.
